Rafael Holdings, Inc. (NYSE:RFL) Short Interest Up 26.3% in March

Rafael Holdings, Inc. (NYSE:RFL) was the recipient of a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 121,900 shares, an increase of 26.3% from the February 28th total of 96,500 shares. Based on an average daily volume of 36,200 shares, the short-interest ratio is presently 3.4 days. Approximately 0.6% of the shares of the company are sold short.

Hedge Funds Weigh In On Rafael

An institutional investor recently raised its position in Rafael stock. Geode Capital Management LLC grew its holdings in shares of Rafael Holdings, Inc. (NYSE:RFL) by 24.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 148,068 shares of the company’s stock after purchasing an additional 29,448 shares during the period. Geode Capital Management LLC owned 0.60% of Rafael worth $287,000 as of its most recent SEC filing. 11.30% of the stock is owned by hedge funds and other institutional investors.

Rafael Stock Performance

RFL stock remained flat at $1.87 on Tuesday. The company had a trading volume of 20,098 shares, compared to its average volume of 30,925. The company has a market cap of $46.59 million, a price-to-earnings ratio of -1.12 and a beta of 1.15. Rafael has a 52-week low of $1.29 and a 52-week high of $2.50. The company has a fifty day moving average of $1.98 and a two-hundred day moving average of $1.92.

Rafael (NYSE:RFL) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.06) earnings per share (EPS) for the quarter. Rafael had a negative return on equity of 53.71% and a negative net margin of 5,707.03%. The firm had revenue of $0.08 million for the quarter.

Rafael Company Profile

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells.